IN2012DN00640A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00640A
IN2012DN00640A IN640DEN2012A IN2012DN00640A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A IN 640DEN2012 A IN640DEN2012 A IN 640DEN2012A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A
Authority
IN
India
Prior art keywords
variable domains
hosts
ligands
vectors
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Coulstock Edward
De Angelis Elena
Liu Haiqun
Schon Oliver
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2012DN00640A publication Critical patent/IN2012DN00640A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN640DEN2012 2009-07-16 2010-07-14 IN2012DN00640A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US30755410P 2010-02-24 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
IN2012DN00640A true IN2012DN00640A (pt) 2015-08-21

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN640DEN2012 IN2012DN00640A (pt) 2009-07-16 2010-07-14

Country Status (15)

Country Link
US (2) US8679496B2 (pt)
EP (1) EP2454285A2 (pt)
JP (1) JP2012532620A (pt)
KR (1) KR20120038494A (pt)
CN (1) CN102574914A (pt)
AU (1) AU2010272590B2 (pt)
BR (1) BR112012001681A2 (pt)
CA (1) CA2768462A1 (pt)
EA (1) EA201270174A1 (pt)
IL (1) IL217520A0 (pt)
IN (1) IN2012DN00640A (pt)
MX (1) MX2012000765A (pt)
SG (1) SG177601A1 (pt)
WO (1) WO2011006915A2 (pt)
ZA (1) ZA201200276B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301335A1 (en) * 2009-02-19 2011-12-08 Stephen Duffield Anti-tnfr1 polypeptides, antibody variable domains & antagonists
CN102574914A (zh) * 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
DK2776466T3 (da) 2011-11-11 2017-11-20 Ucb Biopharma Sprl Albuminbindende antistoffer og bindingsfragmenter deraf
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (pt) 2015-11-12 2018-06-09
CN115925919A (zh) * 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
EP3377526A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及/或 lag3結合劑
CN108473564B (zh) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
CN110049997B (zh) 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
CN117285623A (zh) * 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
JP7300385B2 (ja) * 2017-01-17 2023-06-29 アブリンクス エン.ヴェー. 改善された血清アルブミン結合剤
WO2018151868A2 (en) 2017-02-16 2018-08-23 Sonnet Bio Therapeutics Albumin binding domain fusion proteins
BR112020006999A2 (pt) 2017-10-10 2020-10-06 Numab Therapeutics AG anticorpo multiespecífico, composição farmacêutica e método de produção
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US20220195021A1 (en) * 2019-02-22 2022-06-23 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP4133084A1 (en) 2020-04-09 2023-02-15 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ror1およびcd3に対する特異性を有する多重特異性抗体
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
WO2005118642A2 (en) 2004-06-01 2005-12-15 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070094909A (ko) * 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン1受容体1型に結合する競合ドメイン抗体フォーマット
EA200801170A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
KR20080077261A (ko) * 2005-12-06 2008-08-21 도만티스 리미티드 Egfr 및/또는 vegf에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
EP2297316A2 (en) * 2008-06-06 2011-03-23 Danisco US Inc. Compositions and methods comprising variant microbial proteases
CN102574914A (zh) * 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区

Also Published As

Publication number Publication date
SG177601A1 (en) 2012-02-28
EA201270174A1 (ru) 2012-07-30
MX2012000765A (es) 2012-02-13
WO2011006915A3 (en) 2011-03-03
BR112012001681A2 (pt) 2019-09-24
CA2768462A1 (en) 2011-01-20
AU2010272590A1 (en) 2012-02-02
WO2011006915A2 (en) 2011-01-20
US20140140996A1 (en) 2014-05-22
EP2454285A2 (en) 2012-05-23
AU2010272590B2 (en) 2013-10-10
JP2012532620A (ja) 2012-12-20
ZA201200276B (en) 2012-09-26
US20120114647A1 (en) 2012-05-10
US8679496B2 (en) 2014-03-25
CN102574914A (zh) 2012-07-11
IL217520A0 (en) 2012-02-29
KR20120038494A (ko) 2012-04-23

Similar Documents

Publication Publication Date Title
IN2012DN00640A (pt)
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
MX2012003939A (es) Fusiones y conjugados de farmaco.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2013130683A3 (en) Xten conjugate compositions and methods of making same
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
UA110370C2 (en) Conjugates of amatoxin with improved linkages
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
WO2011086143A3 (en) Liver targeting domain antibodies
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
WO2014044793A3 (en) Cd22-binding peptides
EP2569327A4 (en) EIF4E BINDING PEPTIDES
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
WO2012136792A3 (en) Cck compositions
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.